BRPI0416361A - métodos para regular a quantidade de isoforma 4 de apoe na corrente sanguìnea e/ou cérebro do paciente, para prevenir, tratar ou melhorar os sintomas do mal de alzheimer, para regular a produção de pelo menos um peptìdeos beta amilóide de um paciente ou regular um nìvel de pelo menos um peptìdeo beta amilóide na corrente sangüìnea e/ou cérebro de um paciente, para prevenir ou tratar um tumor associado com o colesterol, e para prevenir ou diminuir a incidência de xantomas em um paciente - Google Patents
métodos para regular a quantidade de isoforma 4 de apoe na corrente sanguìnea e/ou cérebro do paciente, para prevenir, tratar ou melhorar os sintomas do mal de alzheimer, para regular a produção de pelo menos um peptìdeos beta amilóide de um paciente ou regular um nìvel de pelo menos um peptìdeo beta amilóide na corrente sangüìnea e/ou cérebro de um paciente, para prevenir ou tratar um tumor associado com o colesterol, e para prevenir ou diminuir a incidência de xantomas em um pacienteInfo
- Publication number
- BRPI0416361A BRPI0416361A BRPI0416361-3A BRPI0416361A BRPI0416361A BR PI0416361 A BRPI0416361 A BR PI0416361A BR PI0416361 A BRPI0416361 A BR PI0416361A BR PI0416361 A BRPI0416361 A BR PI0416361A
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- prevent
- bloodstream
- brain
- regulate
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 2
- 210000004556 brain Anatomy 0.000 title 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102000001708 Protein Isoforms Human genes 0.000 title 1
- 108010029485 Protein Isoforms Proteins 0.000 title 1
- 206010048215 Xanthomatosis Diseases 0.000 title 1
- 235000012000 cholesterol Nutrition 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/568—Four-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51869803P | 2003-11-10 | 2003-11-10 | |
| US54957704P | 2004-03-03 | 2004-03-03 | |
| US59252904P | 2004-07-30 | 2004-07-30 | |
| US61400504P | 2004-09-28 | 2004-09-28 | |
| PCT/US2004/037715 WO2005047248A1 (en) | 2003-11-10 | 2004-11-10 | 4-biarylyl-1-phenylazetidin-2-ones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0416361A true BRPI0416361A (pt) | 2007-05-08 |
Family
ID=34596124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0416361-3A BRPI0416361A (pt) | 2003-11-10 | 2004-11-10 | métodos para regular a quantidade de isoforma 4 de apoe na corrente sanguìnea e/ou cérebro do paciente, para prevenir, tratar ou melhorar os sintomas do mal de alzheimer, para regular a produção de pelo menos um peptìdeos beta amilóide de um paciente ou regular um nìvel de pelo menos um peptìdeo beta amilóide na corrente sangüìnea e/ou cérebro de um paciente, para prevenir ou tratar um tumor associado com o colesterol, e para prevenir ou diminuir a incidência de xantomas em um paciente |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7320972B2 (https=) |
| EP (1) | EP1682499B1 (https=) |
| JP (1) | JP2007520453A (https=) |
| KR (1) | KR20070050861A (https=) |
| AT (1) | ATE369335T1 (https=) |
| AU (1) | AU2004288822A1 (https=) |
| BR (1) | BRPI0416361A (https=) |
| CA (1) | CA2545058A1 (https=) |
| CY (1) | CY1106982T1 (https=) |
| DE (1) | DE602004008100T2 (https=) |
| DK (1) | DK1682499T3 (https=) |
| EA (1) | EA010026B1 (https=) |
| ES (1) | ES2291974T3 (https=) |
| IL (1) | IL175414A0 (https=) |
| MA (1) | MA28216A1 (https=) |
| MX (1) | MXPA06005106A (https=) |
| NO (1) | NO20062665L (https=) |
| NZ (1) | NZ546940A (https=) |
| PL (2) | PL380414A1 (https=) |
| PT (1) | PT1682499E (https=) |
| WO (1) | WO2005047248A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| AU2004288822A1 (en) * | 2003-11-10 | 2005-05-26 | Microbia, Inc. | 4-Biarylyl-1-phenylazetidin-2-ones |
| EP1699759B1 (en) | 2003-12-23 | 2010-10-20 | AstraZeneca AB | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
| US20090005321A1 (en) * | 2005-02-09 | 2009-01-01 | Microbia, Inc. | Phenylazetidinone Derivatives |
| US20090186834A1 (en) * | 2005-03-24 | 2009-07-23 | Microbia, Inc. | Diphenylheterocycle cholesterol absorption inhibitors |
| WO2006116499A1 (en) * | 2005-04-26 | 2006-11-02 | Microbia, Inc. | 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia |
| US20090131395A1 (en) * | 2005-05-05 | 2009-05-21 | Microbia, Inc. | Biphenylazetidinone cholesterol absorption inhibitors |
| TW200726746A (en) * | 2005-05-06 | 2007-07-16 | Microbia Inc | Processes for production of 4-biphenylylazetidin-2-ones |
| JP2008543744A (ja) * | 2005-05-09 | 2008-12-04 | マイクロビア インコーポレーテッド | 有機金属ベンゼンホスホナートカップリング剤 |
| CA2608075A1 (en) * | 2005-05-11 | 2006-11-16 | Microbia, Inc. | Processes for production of phenolic 4-biphenylylazetidin-2-ones |
| WO2006124713A2 (en) * | 2005-05-13 | 2006-11-23 | Microbia, Inc. | 4-biarylyl-1-phenylazetidin-2-ones |
| EA200702614A1 (ru) * | 2005-05-25 | 2008-04-28 | Майкробиа, Инк. | Способы получения 4-(бифенилил)азетидин-2-оналкилфосфиновых кислот |
| EP1893222A4 (en) * | 2005-06-15 | 2010-07-07 | Merck Sharp & Dohme | ANTI-HYPERCHOLESTERINAMIC COMPOUNDS |
| DE602006010870D1 (de) | 2005-06-20 | 2010-01-14 | Schering Corp | Als antagonisten von histamin h3 geeignete piperidinderivate |
| UY29607A1 (es) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
| MY148538A (en) | 2005-06-22 | 2013-04-30 | Astrazeneca Ab | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
| SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| DE102005055726A1 (de) * | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| WO2008057948A2 (en) * | 2006-11-01 | 2008-05-15 | Ironwood Pharmaceuticals, Inc. | Processes for production of diphenylylazetidin-2-ones and related compounds |
| EP2086324A2 (en) * | 2006-11-02 | 2009-08-12 | Merck & Co., Inc. | Heterocyclyl-substituted anti-hypercholesterolemic compounds |
| JPWO2008108486A1 (ja) | 2007-03-06 | 2010-06-17 | 帝人ファーマ株式会社 | １−ビアリールアゼチジノン誘導体 |
| US20080280836A1 (en) * | 2007-05-08 | 2008-11-13 | Morriello Gregori J | Anti-hypercholesterolemic biaryl azetidinone compounds |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| TW201000107A (en) * | 2008-04-09 | 2010-01-01 | Infinity Pharmaceuticals Inc | Inhibitors of fatty acid amide hydrolase |
| US20090312302A1 (en) * | 2008-06-17 | 2009-12-17 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| CA2757622A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| WO2010118155A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| MX2012001729A (es) | 2009-08-26 | 2012-06-13 | Sanofi Sa | Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo. |
| MX361692B (es) | 2010-02-03 | 2018-12-13 | Infinity Pharmaceuticals Inc | Inhibidores de amida hidrolasa de ácido graso. |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| DK3362462T3 (da) | 2015-10-12 | 2021-10-11 | Advanced Cell Diagnostics Inc | In situ-detektion af nukleotidvarianter i prøver med højt støjniveau, og sammensætninger og fremgangsmåder relateret dertil |
| KR102919209B1 (ko) | 2018-08-10 | 2026-01-28 | 다이아핀 테라퓨틱스, 엘엘씨 | 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US37721A (en) * | 1863-02-17 | Improvement in hose-couplings | ||
| US5688787A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
| US5561227A (en) | 1991-07-23 | 1996-10-01 | Schering Corporation | Process for the stereospecific synthesis of azetidinones |
| US5688785A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| ES2107548T3 (es) * | 1991-07-23 | 1997-12-01 | Schering Corp | Compuestos de beta-lactama sustituidos utiles como agentes hipocolesterolemicos y procedimientos para su preparacion. |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5656624A (en) * | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| HRP20030498A2 (en) | 2000-12-21 | 2005-04-30 | Aventis Pharma Deutschland Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
| WO2002058685A2 (en) * | 2001-01-26 | 2002-08-01 | Schering Corporation | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
| TWI291957B (en) * | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
| HUP0401501A3 (en) * | 2001-09-21 | 2012-02-28 | Schering Corp | Treating or preventing vascular inflammation using pharmaceutical compositions containing sterol absorption inhibitor(s) |
| US20030119808A1 (en) * | 2001-09-21 | 2003-06-26 | Schering Corporation | Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects |
| US7176194B2 (en) * | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| US7176193B2 (en) * | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| EP1682117A1 (en) * | 2003-10-30 | 2006-07-26 | Merck & Co., Inc. | 2-azetidinones as anti-hypercholesterolemic agents |
| AU2004288822A1 (en) * | 2003-11-10 | 2005-05-26 | Microbia, Inc. | 4-Biarylyl-1-phenylazetidin-2-ones |
| CA2608075A1 (en) * | 2005-05-11 | 2006-11-16 | Microbia, Inc. | Processes for production of phenolic 4-biphenylylazetidin-2-ones |
| EA200702614A1 (ru) * | 2005-05-25 | 2008-04-28 | Майкробиа, Инк. | Способы получения 4-(бифенилил)азетидин-2-оналкилфосфиновых кислот |
| DE102005055726A1 (de) * | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| US20080280836A1 (en) * | 2007-05-08 | 2008-11-13 | Morriello Gregori J | Anti-hypercholesterolemic biaryl azetidinone compounds |
-
2004
- 2004-11-10 AU AU2004288822A patent/AU2004288822A1/en not_active Abandoned
- 2004-11-10 BR BRPI0416361-3A patent/BRPI0416361A/pt not_active IP Right Cessation
- 2004-11-10 US US10/986,570 patent/US7320972B2/en not_active Expired - Fee Related
- 2004-11-10 ES ES04810780T patent/ES2291974T3/es not_active Expired - Lifetime
- 2004-11-10 NZ NZ546940A patent/NZ546940A/en unknown
- 2004-11-10 DK DK04810780T patent/DK1682499T3/da active
- 2004-11-10 MX MXPA06005106A patent/MXPA06005106A/es active IP Right Grant
- 2004-11-10 EA EA200600950A patent/EA010026B1/ru not_active IP Right Cessation
- 2004-11-10 KR KR1020067011344A patent/KR20070050861A/ko not_active Ceased
- 2004-11-10 JP JP2006539874A patent/JP2007520453A/ja active Pending
- 2004-11-10 PL PL380414A patent/PL380414A1/pl not_active Application Discontinuation
- 2004-11-10 EP EP04810780A patent/EP1682499B1/en not_active Expired - Lifetime
- 2004-11-10 PL PL04810780T patent/PL1682499T3/pl unknown
- 2004-11-10 PT PT04810780T patent/PT1682499E/pt unknown
- 2004-11-10 AT AT04810780T patent/ATE369335T1/de not_active IP Right Cessation
- 2004-11-10 DE DE602004008100T patent/DE602004008100T2/de not_active Expired - Lifetime
- 2004-11-10 CA CA002545058A patent/CA2545058A1/en not_active Abandoned
- 2004-11-10 WO PCT/US2004/037715 patent/WO2005047248A1/en not_active Ceased
-
2006
- 2006-05-04 IL IL175414A patent/IL175414A0/en unknown
- 2006-05-05 MA MA29006A patent/MA28216A1/fr unknown
- 2006-06-09 NO NO20062665A patent/NO20062665L/no not_active Application Discontinuation
-
2007
- 2007-11-08 CY CY20071101429T patent/CY1106982T1/el unknown
- 2007-12-11 US US11/954,170 patent/US20080167255A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20080167255A1 (en) | 2008-07-10 |
| DE602004008100T2 (de) | 2008-04-30 |
| CY1106982T1 (el) | 2012-09-26 |
| DK1682499T3 (da) | 2008-01-02 |
| US20050209165A1 (en) | 2005-09-22 |
| MXPA06005106A (es) | 2007-01-25 |
| PL380414A1 (pl) | 2007-01-22 |
| US7320972B2 (en) | 2008-01-22 |
| EP1682499B1 (en) | 2007-08-08 |
| WO2005047248A1 (en) | 2005-05-26 |
| CA2545058A1 (en) | 2005-05-26 |
| EA200600950A1 (ru) | 2006-10-27 |
| ES2291974T3 (es) | 2008-03-01 |
| AU2004288822A1 (en) | 2005-05-26 |
| DE602004008100D1 (de) | 2007-09-20 |
| NO20062665L (no) | 2006-08-09 |
| MA28216A1 (fr) | 2006-10-02 |
| NZ546940A (en) | 2008-11-28 |
| PL1682499T3 (pl) | 2008-01-31 |
| JP2007520453A (ja) | 2007-07-26 |
| IL175414A0 (en) | 2006-09-05 |
| PT1682499E (pt) | 2007-11-05 |
| HK1093974A1 (en) | 2007-03-16 |
| ATE369335T1 (de) | 2007-08-15 |
| KR20070050861A (ko) | 2007-05-16 |
| EA010026B1 (ru) | 2008-06-30 |
| EP1682499A1 (en) | 2006-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0416361A (pt) | métodos para regular a quantidade de isoforma 4 de apoe na corrente sanguìnea e/ou cérebro do paciente, para prevenir, tratar ou melhorar os sintomas do mal de alzheimer, para regular a produção de pelo menos um peptìdeos beta amilóide de um paciente ou regular um nìvel de pelo menos um peptìdeo beta amilóide na corrente sangüìnea e/ou cérebro de um paciente, para prevenir ou tratar um tumor associado com o colesterol, e para prevenir ou diminuir a incidência de xantomas em um paciente | |
| RU2498988C2 (ru) | Ингибиторы активности протеинтирозинкиназы | |
| BRPI0412893A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto | |
| EP1841426A4 (en) | ACTIVE TERTIARY CARBINAMINES WITH SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF ALZHEIMER DISEASE AS INHIBITORS OF BETA-SECRETASE | |
| EP1562897A4 (en) | PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER | |
| DE69429527D1 (de) | Inhibitoren von beta-amyloid-protein-herstellung | |
| MA28935B1 (fr) | Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite | |
| MX339524B (es) | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. | |
| EA200601239A1 (ru) | Замещённые хинолиновые соединения | |
| BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
| WO2008061795A3 (en) | N- (methyl) -1h- pyrazol- 3 -amine, n- (methyl) -pyridin-2-amine and n- (methyl) -thiaz0l-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| UY28280A1 (es) | 2- hidroxi - 3- diaminoalcanos de benzamida | |
| BR0312851A (pt) | Composto, composição farmacêutica, e, métodos para tratar ou previnir câncer, degeneração macular de tipo úmido ou artrite reumatóide, vascularização anÈmala, nìveis de cobre em excesso em um paciente, obesidade e doença neurodegenerativa em um paciente | |
| BRPI0517947A (pt) | composto de piridazina, composições e métodos | |
| TW200744630A (en) | Therapeutic vaccine | |
| UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
| DE60226729D1 (de) | Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| EP1543158A4 (en) | REGULATED APTAMER THERAPEUTICS | |
| DE60221283D1 (de) | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden | |
| BR0314180A (pt) | Aminoéteres substituìdos para o tratamento da doença de alzheimer | |
| DE60108130D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
| NO20052153L (no) | Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer. | |
| ATE506961T1 (de) | Ccn3 proteine zur behandlung und diagnose von nierenerkrankungen | |
| ATE214926T1 (de) | Verwendung von (r-(z))-alpha-(methoxyimino)-alpha-(1-azabicycl (2.2.2.) oct-3-yl) acetonitril zur hemmung der amyloid-beta-a4-bildung bei der alzheimerschen krankheit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |